AMAG Pharmaceuticals announced plans to acquire Perosphere Pharmaceuticals for up to $415 million, and AMAG said the acquisition would expand its hematology pipeline with access to Perosphere's ciraparantag, or PER977, a next-generation anticoagulant reversal drug. Perosphere could receive up to $140 million in payments linked to regulatory milestones achieved in the US and approval from European regulators.
AMAG to expand hematology pipeline with Perosphere acquisition
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.